Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Judge

Showing results (201-210 of 353) with videos related to

Pageof 36
Sort By:
Circulation. Genomic and Precision Medicine|April 22, 2026
Scalable System-Wide CYP2C19 Pharmacogenomic Testing Reveals 38% Excess Incidence of Adverse Events in Metabolizers Receiving Inappropriate PrescriptionsNatalie Telis, Douglas Stoller, Christopher N Chapman, et al.
Implementation Science Communications|April 28, 2022
A pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populationsCaitlin G Allen, Daniel P Judge, Elissa Levin, et al.
Journal of the American Heart Association|June 8, 2017
Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and ComplicationsGabriela M Orgeron, Cynthia A James, Anneline Te Riele, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 13, 2017
Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosisEmily E Brown, Yi Zhen Joan Lee, Marc K Halushka, et al.
American Journal of Human Genetics|June 15, 2006
DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathyMark M Awad, Darshan Dalal, Eunpi Cho, et al.
Journal of Cardiac Failure|December 25, 2016
Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial BiopsyVan-Khue Ton, Aditya Bhonsale, Nisha A Gilotra, et al.
Circulation. Genomic and Precision Medicine|July 13, 2018
Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical SurveillanceChristopher M Haggerty, Brittney Murray, Crystal Tichnell, et al.
The Journal of Clinical Investigation|November 17, 2004
TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndromeConnie M Ng, Alan Cheng, Loretha A Myers, et al.
Communications Medicine|November 20, 2024
Underestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetesKelly M Schiabor Barrett, Natalie Telis, Lisa M McEwen, et al.
Heart Rhythm|May 8, 2009
Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathyHarikrishna Tandri, Angeliki Asimaki, Theodore Abraham, et al.
Pageof 36

Showing results (201-210 of 353) with videos related to

Sort By:
Pageof 36
Circulation. Genomic and Precision Medicine|April 22, 2026
Scalable System-Wide CYP2C19 Pharmacogenomic Testing Reveals 38% Excess Incidence of Adverse Events in Metabolizers Receiving Inappropriate PrescriptionsNatalie Telis, Douglas Stoller, Christopher N Chapman, et al.
Implementation Science Communications|April 28, 2022
A pragmatic implementation research study for In Our DNA SC: a protocol to identify multi-level factors that support the implementation of a population-wide genomic screening initiative in diverse populationsCaitlin G Allen, Daniel P Judge, Elissa Levin, et al.
Journal of the American Heart Association|June 8, 2017
Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and ComplicationsGabriela M Orgeron, Cynthia A James, Anneline Te Riele, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 13, 2017
Genetic testing improves identification of transthyretin amyloid (ATTR) subtype in cardiac amyloidosisEmily E Brown, Yi Zhen Joan Lee, Marc K Halushka, et al.
American Journal of Human Genetics|June 15, 2006
DSG2 mutations contribute to arrhythmogenic right ventricular dysplasia/cardiomyopathyMark M Awad, Darshan Dalal, Eunpi Cho, et al.
Journal of Cardiac Failure|December 25, 2016
Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial BiopsyVan-Khue Ton, Aditya Bhonsale, Nisha A Gilotra, et al.
Circulation. Genomic and Precision Medicine|July 13, 2018
Managing Secondary Genomic Findings Associated With Arrhythmogenic Right Ventricular Cardiomyopathy: Case Studies and Proposal for Clinical SurveillanceChristopher M Haggerty, Brittney Murray, Crystal Tichnell, et al.
The Journal of Clinical Investigation|November 17, 2004
TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndromeConnie M Ng, Alan Cheng, Loretha A Myers, et al.
Communications Medicine|November 20, 2024
Underestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetesKelly M Schiabor Barrett, Natalie Telis, Lisa M McEwen, et al.
Heart Rhythm|May 8, 2009
Prolonged RV endocardial activation duration: a novel marker of arrhythmogenic right ventricular dysplasia/cardiomyopathyHarikrishna Tandri, Angeliki Asimaki, Theodore Abraham, et al.
Pageof 36